12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ETBX-011: Phase I/II data

An open-label, U.S. Phase I/II trial in 25 patients with refractory advanced CEA-expressing colorectal cancer showed that subcutaneous ETBX-011 given once every 3 weeks for 3...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >